Literature DB >> 7048991

Safer sedation for ventilated patients. A new application for etomidate.

D L Edbrooke, D M Newby, S J Mather, A M Dixon, B S Hebron.   

Abstract

A technique is described for sedation of ventilated patients. Six patients who underwent major maxillofacial surgery were given low dose infusions of etomidate and fentanyl for postoperative sedation. Measurements of respiratory function were recorded before and during the period of intermittent positive pressure ventilation. Plasma etomidate levels were estimated. After initial stabilisation on almost constant rate of infusion was used to provide a reproducible level of sedation from which the patients were easily aroused. All patients maintained an adequate minute volume when disconnected from the ventilator. All measured and derived respiratory indices remained within normal limits. Patients exhibited amnesia throughout the period of infusion. All patients found this method of sedation pleasant. This technique may be recommended as an alternative to conventional methods of sedation for ventilated patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7048991     DOI: 10.1111/j.1365-2044.1982.tb01319.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  4 in total

Review 1.  Clinical and molecular pharmacology of etomidate.

Authors:  Stuart A Forman
Journal:  Anesthesiology       Date:  2011-03       Impact factor: 7.892

Review 2.  Anaesthetic considerations for microsurgical repair of limbs.

Authors:  T M Bird; L Strunin
Journal:  Can Anaesth Soc J       Date:  1984-01

3.  Adrenocortical suppression in multiply injured patients: a complication of etomidate treatment.

Authors:  I W Fellows; M D Bastow; A J Byrne; S P Allison
Journal:  Br Med J (Clin Res Ed)       Date:  1983-12-17

Review 4.  Pharmacological management of severe Cushing's syndrome: the role of etomidate.

Authors:  Andrea Pence; Megan McGrath; Stephanie L Lee; Douglas E Raines
Journal:  Ther Adv Endocrinol Metab       Date:  2022-02-14       Impact factor: 3.565

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.